Compare COUR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COUR | SNDX |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2021 | 2014 |
| Metric | COUR | SNDX |
|---|---|---|
| Price | $5.58 | $19.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $10.53 | ★ $38.69 |
| AVG Volume (30 Days) | ★ 6.9M | 1.3M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.22 | 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $757,500,000.00 | $172,352,000.00 |
| Revenue This Year | $9.43 | $107.19 |
| Revenue Next Year | $6.40 | $41.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 9.04 | ★ 627.84 |
| 52 Week Low | $5.00 | $13.00 |
| 52 Week High | $12.32 | $25.59 |
| Indicator | COUR | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.73 | 48.25 |
| Support Level | $5.20 | $19.28 |
| Resistance Level | $6.39 | $22.40 |
| Average True Range (ATR) | 0.28 | 1.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 48.89 | 84.57 |
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through two reporting segments: Consumer and Enterprise. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.